Reshape Biotech vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Copenhagen YC W21 lab automation robots for biotech at $28.2M total ($20M Astanor Series A Apr 2024) and $8.3M revenue 2024; 500K+ hours saved annually serving alternative protein and sustainable ag competing with Opentrons for microbiology automation.
About
Reshape Biotech is a Copenhagen, Denmark-based laboratory automation robotics company — backed by Y Combinator (W21) with $28.2 million in total funding including a $20 million Series A led by Astanor Ventures in April 2024 with participation from YC — providing biotechnology companies, life sciences research organizations, and food technology companies with specialized single-function robots that automate repetitive microbiological laboratory workflows, generating $8.3 million in annual revenue in 2024 with a 55-person team. Reshape's robots have saved customers over 500,000 hours of manual lab work annually, serving the sustainable food technology and alternative protein sector (fermentation-based food production, precision fermentation, cultivated meat) alongside traditional biotech research laboratories that use microbiology workflows at scale.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.